NEW YORK (360Dx) – Fulgent Genetics reported after the close of the market on Monday that its first quarter revenues fell 11 percent year over year.

For the three months ended March 31, the Temple City, California-based company posted $4.7 million in revenues, down from $5.3 million in Q1 2017. The firm delivered 4,621 billable tests in Q1 2018.

Despite the revenue decline, the billable test volume was the highest in a quarter in the company's history, Fulgent Chairman and CEO Ming Hsieh said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.